Overview

Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty

Status:
Unknown status
Trial end date:
2016-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study, therefore, is to conduct a prospective randomized controlled trial to investigate the blood-conservation effect of TXA in different TKA patients groups with rivaroxaban for VTE prophylaxis, first group by topical application, second group by infusion and a third group of placebo and observe whether there is difference in the occurrence of venous thromboembolism in those patient groups by venographic study
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Chang Gung Memorial Hospital
Treatments:
Rivaroxaban
Tranexamic Acid
Tranylcypromine
Criteria
Inclusion Criteria:

- End-stage arthritis of the knee

- Failure of medical treatment or rehabilitation

- Hemoglobin > 10g/dl

- No use of non-steroid anti-inflammatory agent one week before operation

Exclusion Criteria:

- Preoperative Hemoglobin ≦10 g/dl

- History of infection or intraarticular fracture of the affective knee

- Renal function deficiency (GFR < 55 ml/min/1.73m2)which is relative contraindicated
for venography

- Elevated liver enzyme, history of liver cirrhosis, impaired liver function and
coagulopathy (including long-term use anticoagulant)

- History of deep vein thrombosis, ischemic heart disease or stroke